Menu

Question 2341

Topic: Biology, Genetics & Bone Healing

A 5-year-old girl with severe Osteogenesis Imperfecta (OI) is receiving intravenous pamidronate infusions to increase bone mineral density and reduce fracture frequency. Which of the following best describes the molecular mechanism of action of this medication?

. Stimulates osteoblast differentiation via the Wnt/beta-catenin pathway
. Inhibits RANKL to prevent osteoclast activation
. Inhibits farnesyl pyrophosphate (FPP) synthase in the mevalonate pathway
. Directly cross-links collagen fibers in the bone matrix
. Binds to hydroxyapatite and acts as a localized calcium channel blocker

Correct Answer & Explanation

. Inhibits farnesyl pyrophosphate (FPP) synthase in the mevalonate pathway


Explanation

Pamidronate is a nitrogen-containing bisphosphonate. It works by inhibiting farnesyl pyrophosphate (FPP) synthase in the mevalonate pathway, which leads to osteoclast apoptosis and reduced bone resorption.

Question 2342

Topic: Biology, Genetics & Bone Healing

A 12-year-old with multiple fractures has a bone biopsy that demonstrates a distinctive 'fish-scale' lamellation pattern under polarized light microscopy. The patient has shown no clinical improvement with prolonged bisphosphonate therapy. This presentation is most consistent with a mutation in which gene?

. COL1A1
. IFITM5
. SERPINF1
. CRTAP
. LEPRE1

Correct Answer & Explanation

. IFITM5


Explanation

OI Type VI is caused by a mutation in the SERPINF1 gene, which encodes pigment epithelium-derived factor (PEDF). It is characterized histologically by a 'fish-scale' pattern of bone lamellation and typically does not respond to bisphosphonates.

Question 2343

Topic: Biology, Genetics & Bone Healing

A 4-year-old boy with SMA is prescribed Risdiplam. Which of the following accurately describes the administration and mechanism of this medication?

. Intrathecal injection; directly repairs the SMN1 gene
. Intravenous infusion; viral vector delivery of SMN1
. Oral administration; small molecule modifier of SMN2 pre-mRNA splicing
. Intramuscular injection; downregulates myostatin
. Subcutaneous injection; inhibits osteoclast-mediated bone loss

Correct Answer & Explanation

. Oral administration; small molecule modifier of SMN2 pre-mRNA splicing


Explanation

Risdiplam is an orally administered small molecule that modifies the splicing of the SMN2 pre-mRNA, leading to an increased concentration of functional full-length SMN protein.

Question 2344

Topic: Biology, Genetics & Bone Healing
A 2-year-old boy with OI type III receives his first intravenous infusion of pamidronate. Within 24 hours, he develops a fever of 38.5°C, myalgia, and vomiting. What is the most appropriate management of these symptoms?
. Immediate discontinuation of pamidronate permanently due to anaphylaxis
. Administration of broad-spectrum intravenous antibiotics
. Supportive care with antipyretics, as this is a common first-dose acute phase reaction
. Administration of intravenous calcium gluconate for severe hypocalcemia
. Immediate surgical debridement of the infusion site

Correct Answer & Explanation

. Supportive care with antipyretics, as this is a common first-dose acute phase reaction


Explanation

The 'acute phase reaction' is very common (up to 70-80%) after the first infusion of nitrogen-containing bisphosphonates like pamidronate. It consists of fever, myalgias, and flu-like symptoms, which are self-limiting and managed with supportive care.

Question 2345

Topic: Biology, Genetics & Bone Healing
Which of the following cellular processes accurately describes how a fracture heals in a patient with classical Osteogenesis Imperfecta (Type I, III, or IV)?
. Fracture healing is severely delayed with frequent nonunions due to absent osteoblasts.
. Fracture healing occurs at a normal rate with normal callus formation, but the resulting bone is structurally inferior.
. Fracture healing relies exclusively on primary (intramembranous) bone healing, as endochondral ossification is blocked.
. Fractures fail to heal without exogenous bone morphogenetic protein (BMP) administration.
. Fracture healing results in dense, sclerotic bone that is mechanically stronger than the original diaphysis.

Correct Answer & Explanation

. Fracture healing occurs at a normal rate with normal callus formation, but the resulting bone is structurally inferior.


Explanation

In OI, the physiological cascade of fracture healing and callus formation occurs at a normal rate. However, because the collagen matrix is defective (either quantitatively or qualitatively), the newly formed bone remains structurally inferior and prone to re-fracture.

Question 2346

Topic: Biology, Genetics & Bone Healing

A 6-month-old infant presents with multiple fractures of varying ages, blue sclerae, and generalized osteopenia. Genetic testing reveals a mutation in the COL1A1 gene. Which of the following is the primary mechanism of action of the most commonly prescribed class of medications (bisphosphonates) used to treat this condition?

. Inhibition of osteoclast-mediated bone resorption
. Stimulation of osteoblast proliferation and differentiation
. Enhancement of calcium and phosphate absorption in the gut
. Increased synthesis of structurally normal type I collagen
. Direct inhibition of parathyroid hormone secretion

Correct Answer & Explanation

. Inhibition of osteoclast-mediated bone resorption


Explanation

Osteogenesis Imperfecta (OI) is treated medically with bisphosphonates (e.g., pamidronate or zoledronic acid). Bisphosphonates are analogues of inorganic pyrophosphate that bind to hydroxyapatite and function primarily by inhibiting osteoclast-mediated bone resorption, thereby increasing bone mineral density and decreasing the fracture rate.

Question 2347

Topic: Biology, Genetics & Bone Healing
A 4-year-old child with Osteogenesis Imperfecta (OI) type III is treated with intravenous pamidronate. What is the primary cellular mechanism of action by which this medication improves bone density and reduces fracture burden in this patient population?
. Stimulation of osteoblast-mediated bone formation
. Inhibition of osteoclast-mediated bone resorption
. Enhancement of Type I collagen cross-linking
. Direct mineralization of the osteoid matrix
. Upregulation of the Wnt/beta-catenin pathway

Correct Answer & Explanation

. Inhibition of osteoclast-mediated bone resorption


Explanation

Bisphosphonates (such as pamidronate) are the medical treatment of choice for moderate to severe Osteogenesis Imperfecta. They function by inhibiting osteoclast activity and inducing osteoclast apoptosis, thereby decreasing bone resorption. This leaves osteoblast activity unopposed, increasing bone volume and density, though it does not correct the underlying genetic defect in Type I collagen synthesis.

Question 2348

Topic: Biology, Genetics & Bone Healing

A 65-year-old female on long-term alendronate therapy for osteoporosis presents with atraumatic thigh pain. Radiographs demonstrate focal lateral cortical thickening of the subtrochanteric femur with a transverse radiolucent line. Which of the following is the primary pathophysiologic mechanism leading to this atypical femur fracture (AFF)?

. Excessive osteoblastic proliferation causing disorganized woven bone
. Severe suppression of targeted osteoclastic bone remodeling leading to accumulation of microdamage
. Depletion of uncarboxylated osteocalcin leading to brittle collagen cross-linking
. Spontaneous localized osteonecrosis of the lateral cortex
. Increased parathyroid hormone (PTH) activity secondary to bisphosphonate use

Correct Answer & Explanation

. Severe suppression of targeted osteoclastic bone remodeling leading to accumulation of microdamage


Explanation

Bisphosphonates profoundly suppress osteoclast function and apoptosis. Prolonged use (typically > 5 years) severely impairs targeted bone remodeling. Normally, microcracks from daily stress are repaired by basic multicellular units (BMUs). Suppressed remodeling allows these microcracks to accumulate, particularly on the tensile side of the femur (lateral cortex), eventually coalescing into an atypical femur fracture.

Question 2349

Topic: Biology, Genetics & Bone Healing

A neonate is evaluated for short-limbed dwarfism, a 'hitchhiker' thumb, clubfeet, and swelling of the external ear (cauliflower ear). This condition is inherited in an autosomal recessive manner. What is the underlying pathophysiologic defect?

. Defective osteoclast carbonic anhydrase II
. Defective intracellular transport of sulfate
. Impaired cleavage of type I procollagen
. Abnormal fibroblast growth factor signaling
. Defect in beta-glucuronidase

Correct Answer & Explanation

. Defective intracellular transport of sulfate


Explanation

Diastrophic dysplasia is caused by a mutation in the SLC26A2 gene, leading to a defect in the sulfate transport system and resulting in undersulfated proteoglycans in cartilage.

Question 2350

Topic: Biology, Genetics & Bone Healing

A 12-year-old girl is noted to have excessive shoulder mobility, allowing her to touch her shoulders together anteriorly. She also has delayed eruption of secondary teeth. A mutation in which of the following transcription factors is responsible?

. SOX9
. RUNX2 (CBFA1)
. TWIST
. SHH (Sonic Hedgehog)
. HOXD13

Correct Answer & Explanation

. RUNX2 (CBFA1)


Explanation

Cleidocranial dysplasia is caused by a mutation in RUNX2 (CBFA1), a master transcription factor for osteoblast differentiation. It is characterized by absent or hypoplastic clavicles and delayed cranial suture closure.

Question 2351

Topic: Biology, Genetics & Bone Healing

A 35-year-old woman presents with a large, lytic, epiphyseal lesion of the distal femur that extends to the subchondral bone. Biopsy confirms a Giant Cell Tumor of bone. Medical management with denosumab is planned. Denosumab targets which of the following?

. RANK receptor on osteoblasts
. RANK ligand (RANKL)
. Osteoprotegerin (OPG)
. Vascular endothelial growth factor (VEGF)
. Colony-stimulating factor 1 receptor (CSF1R)

Correct Answer & Explanation

. RANK ligand (RANKL)


Explanation

Denosumab is a monoclonal antibody that binds to RANKL, preventing it from activating the RANK receptor on osteoclast precursors. This inhibits osteoclast-mediated bone destruction in giant cell tumors.

Question 2352

Topic: Biology, Genetics & Bone Healing

A 32-year-old female presents with knee pain. Radiographs show an eccentric, lytic lesion in the distal femoral epiphysis reaching the subchondral bone. Biopsy confirms Giant Cell Tumor of Bone. When utilizing Denosumab for unresectable disease, what is the specific molecular target?

. RANK receptor expressed on the multinucleated giant cells
. RANKL expressed on the neoplastic mononuclear stromal cells
. Vascular Endothelial Growth Factor (VEGF)
. Colony Stimulating Factor 1 (CSF-1)
. Fibroblast Growth Factor Receptor 3 (FGFR3)

Correct Answer & Explanation

. RANKL expressed on the neoplastic mononuclear stromal cells


Explanation

In a Giant Cell Tumor, the neoplastic cells are the mononuclear stromal cells, which express RANK Ligand (RANKL). Denosumab is a monoclonal antibody that binds to this RANKL, inhibiting the recruitment and activation of the reactive osteoclast-like giant cells.

Question 2353

Topic: Biology, Genetics & Bone Healing

A 7-year-old boy presents with a waddling gait, bilateral knee pain, and mild short stature. Lateral knee radiographs demonstrate a classic "double-layer" patella. A diagnosis of Multiple Epiphyseal Dysplasia (MED) is suspected. A mutation in which gene is most commonly implicated?

. COL2A1
. COMP
. FGFR3
. RUNX2
. SOX9

Correct Answer & Explanation

. COMP


Explanation

Mutations in COMP (Cartilage Oligomeric Matrix Protein) are the most common cause of Multiple Epiphyseal Dysplasia. A double-layer patella on a lateral knee radiograph is highly characteristic of MED.

Question 2354

Topic: Biology, Genetics & Bone Healing

An 8-year-old girl is referred for evaluation of unusually delayed tooth eruption. On examination, she is noted to have a large head, delayed closure of cranial sutures, and she is able to easily bring her shoulders together anteriorly. Which genetic mutation is highly characteristic of this condition?

. FGFR3
. COMP
. COL1A1
. SOX9
. RUNX2 (CBFA1)

Correct Answer & Explanation

. RUNX2 (CBFA1)


Explanation

The patient has Cleidocranial Dysplasia, typified by hypoplastic or absent clavicles, delayed suture closure, and retained deciduous teeth. It is an autosomal dominant condition caused by mutations in RUNX2 (also known as CBFA1), a crucial transcription factor for osteoblast differentiation.

Question 2355

Topic: Biology, Genetics & Bone Healing

A 32-year-old female presents with knee pain. Radiographs demonstrate an eccentric, lytic, epiphyseal-metaphyseal lesion in the proximal tibia extending to the subchondral bone. Histopathology reveals abundant multinucleated giant cells distributed uniformly among mononuclear stromal cells. The neoplastic mononuclear cells in this tumor typically express high levels of which molecule to drive local bone destruction?

. Osteoprotegerin (OPG)
. Parathyroid hormone-related protein (PTHrP)
. Receptor activator of nuclear factor kappa-B ligand (RANKL)
. Macrophage colony-stimulating factor (M-CSF)
. Sclerostin

Correct Answer & Explanation

. Receptor activator of nuclear factor kappa-B ligand (RANKL)


Explanation

In a Giant Cell Tumor of bone, the neoplastic cells are the mononuclear stromal cells, which express high levels of RANKL. This recruits and stimulates normal host osteoclast precursors to form the characteristic multinucleated giant cells, leading to aggressive bone resorption.

Question 2356

Topic: Biology, Genetics & Bone Healing

A 12-year-old boy presents with an unusual ability to appose his shoulders anteriorly across his chest. Examination reveals an open anterior fontanelle, delayed eruption of his secondary dentition, and a somewhat prominent forehead. Radiographs show hypoplasia of the clavicles. Which essential transcription factor for osteoblast differentiation is mutated in this condition?

. SOX9
. RUNX2 (CBFA1)
. NFATc1
. Osterix (Sp7)
. C-fos

Correct Answer & Explanation

. RUNX2 (CBFA1)


Explanation

The patient has Cleidocranial Dysplasia, characterized by hypoplastic/absent clavicles, delayed suture closure, and dental anomalies. It is an autosomal dominant condition caused by a mutation in RUNX2 (CBFA1), a master transcription factor essential for osteoblast differentiation.

Question 2357

Topic: Biology, Genetics & Bone Healing

A 30-year-old female presents with mechanical knee pain. Imaging reveals an eccentric, purely lytic epiphyseal lesion of the distal femur extending to the subchondral bone. Biopsy confirms numerous multinucleated giant cells. Which of the following targeted systemic therapies is indicated for unresectable forms of this disease?

. Imatinib
. Denosumab
. Rituximab
. Bevacizumab
. Infliximab

Correct Answer & Explanation

. Denosumab


Explanation

Giant Cell Tumor (GCT) of bone is driven by RANKL-secreting stromal cells that recruit osteoclast-like giant cells. Denosumab, a monoclonal antibody against RANKL, is highly effective for unresectable or recurrent GCTs.

Question 2358

Topic: Biology, Genetics & Bone Healing

A 9-year-old child presents with a waddling gait, bilateral knee pain, and short stature. Radiographs demonstrate small, irregular, fragmented epiphyses and a characteristic "double-layered" patella. A mutation in which of the following genes is most highly associated with this specific classic presentation?

. COL1A1
. COMP
. FGFR3
. RUNX2
. SOX9

Correct Answer & Explanation

. COMP


Explanation

Multiple Epiphyseal Dysplasia (MED) commonly presents with delayed, irregular ossification of the epiphyses. The finding of a 'double-layered' patella on a lateral radiograph is virtually pathognomonic and is classically associated with mutations in the COMP gene.

Question 2359

Topic: Biology, Genetics & Bone Healing

A 35-year-old woman presents with a lytic lesion in the distal femur. Biopsy reveals a benign, locally aggressive tumor characterized by mononuclear stromal cells and numerous multinucleated giant cells. Which of the following describes the cellular target of denosumab in the medical management of this tumor?

. It binds to RANK on the surface of the multinucleated giant cells
. It binds to RANKL expressed by the neoplastic mononuclear stromal cells
. It inhibits the IDH1 enzyme within the stromal cells
. It blocks the FGFR3 receptor on osteoblasts
. It inhibits the USP6 ubiquitin-specific protease

Correct Answer & Explanation

. It binds to RANKL expressed by the neoplastic mononuclear stromal cells


Explanation

In Giant Cell Tumor of bone, the mononuclear stromal cells are the true neoplastic cells and heavily express RANKL. Denosumab is a monoclonal antibody that binds to RANKL, preventing it from activating RANK on the osteoclast-like giant cells, thereby reducing bone resorption.

Question 2360

Topic: Biology, Genetics & Bone Healing

A newborn is noted to have a large anterior fontanelle, midface hypoplasia, and excessive mobility of the shoulders, allowing them to be opposed anteriorly. A mutation in the RUNX2 (CBFA1) gene is suspected. What is the primary role of the protein encoded by this gene?

. It is an essential structural component of articular cartilage
. It is a master transcription factor for osteoblast differentiation
. It acts as an inhibitor of osteoclastogenesis
. It is a transmembrane sulfate transporter
. It forms the cross-links in mature type I collagen

Correct Answer & Explanation

. It is a master transcription factor for osteoblast differentiation


Explanation

Cleidocranial dysplasia is caused by a mutation in RUNX2 (also known as CBFA1). RUNX2 is a crucial transcription factor required for the commitment and differentiation of mesenchymal stem cells into the osteoblast lineage.